PTGS2 and metastatic colorectal cancer: Furthermore, analysis of tissue samples from 130 participants in the IMC-0144 trial of cetuximab in patients with metastatic colorectal cancer showed that polymorphisms in PTGS2, which encodes COX-2, and EGFR predicted progression-free survival independently of K-RAS mutation status [21].